What is CorMedix?
CorMedix Inc. is a biopharmaceutical firm dedicated to developing and commercializing therapeutic products aimed at combating infectious and inflammatory diseases. Headquartered in Berkeley Heights, New Jersey, the company's primary focus is on its lead product candidate, DefenCath. This innovative antimicrobial catheter lock solution is designed to mitigate the incidence of catheter-related bloodstream infections, particularly in adult patients undergoing kidney failure treatment. Formerly known as Picton Holding Company, Inc., CorMedix Inc. has been operating under its current name since January 2007, following its incorporation in 2006.
How much funding has CorMedix raised?
CorMedix has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (2010): $12.5M, investors not publicly disclosed
What's next for CorMedix?
The substantial enterprise-level funding CorMedix Inc. has attracted, including its recent strategic investment, signals a critical phase of growth and market penetration. This capital is expected to accelerate the advancement of DefenCath through regulatory pathways and towards broader market availability. The company's strategic focus on addressing catheter-related bloodstream infections, a significant concern in healthcare, positions it to capture a substantial share of the medical device and biopharmaceutical market. Future developments will likely involve scaling manufacturing capabilities, expanding clinical trial initiatives, and forging key commercial partnerships to maximize the impact of its therapeutic solutions.
See full CorMedix company page
